| Literature DB >> 33208829 |
Federica Rota1, Luca Ferrari1, Mirjam Hoxha1, Chiara Favero1, Rita Antonioli1, Laura Pergoli1, Maria Francesca Greco2, Jacopo Mariani1, Lorenza Lazzari3, Valentina Bollati4.
Abstract
The release of Extracellular Vesicles (EVs) into the bloodstream is positively associated with Particulate Matter (PM) exposure, which is involved in endothelial dysfunction and related to increased risk of cardiovascular disease. Obesity modifies the effects of PM exposure on heart rate variability and markers of inflammation, oxidative stress, and acute phase response. We isolated and characterized plasmatic EVs from six healthy donors and confirmed a positive association with PM exposure. We stratified for Body Mass Index (BMI) and observed an increased release of CD61+ (platelets) and CD105+ (endothelium) derived-EVs after high PM level exposure in Normal Weight subjects (NW) and no significant variations in Overweight subjects (OW). We then investigated the ability to activate endothelial primary cells by plasmatic EVs after both high and low PM exposure. NW-high-PM EVs showed an increased endothelial activation, measured as CD105+/CD62e+ (activated endothelium) EVs ratio. On the contrary, cells treated with OW-high-PM EVs showed reduced endothelial activation. These results suggest the ability of NW plasmatic EVs to communicate to endothelial cells and promote the crosstalk between activated endothelium and peripheral cells. However, this capacity was lost in OW subjects. Our findings contribute to elucidate the role of EVs in endothelial activation after PM exposure.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33208829 PMCID: PMC7674466 DOI: 10.1038/s41598-020-77097-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Experimental plan. U.C. ultra-centrifiuged; NTA nanoparticle tracking analysis; EBM-2 endothelial basal medium 2; EVs extracellular vesicles.
Descriptive statistics of PM10 and PM2.5 exposure levels from day-1 to day-7 prior to blood drawings.
| Day-1 | Day-2 | Day-3 | Day -4 | Day-5 | Day-6 | Day-7 | ||
|---|---|---|---|---|---|---|---|---|
| High PM | CTM municipality of domicile | 100 (73—146) | 112 ± 23 | 90 ± 16 | 83 ± 11 | 77 ± 9 | 69 ± 18 | 67 ± 23 |
| CTM municipality of Milan | 119 ± 53 | 107 ± 26 | 79 ± 25 | 78 ± 5 | 75 ± 5 | 68 ± 6 | 89 ± 7 | |
| Low PM | CTM municipality of domicile | 19 (18—24) | 16 (11—21) | 14 ± 4 | 18 ± 8 | 34 ± 22 | 30 ± 14 | 37 ± 24 |
| CTM municipality of Milan | 34 ± 18 | 27 ± 19 | 17 ± 1 | 27 ± 4 | 38 ± 27 | 30 ± 24 | 40 ± 39 | |
| High PM | CTM municipality of domicile | 88 ± 30 | 86 (82—104) | 72 ± 11 | 69 ± 10 | 60 ± 6 | 50 ± 14 | 47 ± 12 |
| CTM municipality of Milan | 98 ± 36 | 90 ± 22 | 72 ± 11 | 67 ± 12 | 64 ± 14 | 60 ± 16 | 67 ± 1 | |
| Low PM | CTM municipality of domicile | 16 ± 9 | 15 ± 12 | 10 (9—14) | 19 ± 6 | 29 ± 18 | 20 ± 13 | 28 ± 19 |
| CTM municipality of Milan | 23 ± 13 | 23 (14—31) | 15 ± 2 | 24 ± 8 | 30 (22—37) | 21 ± 13 | 33 (23—44) | |
Continuous variables were expressed as mean ± standard deviation (SD) or as median [first quartile-third quartile], if not normally distributed.
Figure 2(A) EV concentration means (count *106/mL PL) for each size (nm) from subjects exposed to low-PM and high-PM levels. (B) For each size P-value and False Discovery Rate. P-value from poisson regression models with repeated meausured are reported.
Mean concentrations of plasmatic EV subtypes deriving from subjects exposed to low-PM and high-PM levels.
| EV characterization (*103/mL PL) | Low-PM | High-PM | P-value | ||
|---|---|---|---|---|---|
| Mean | 95% CI | Mean | 95% CI | ||
| CD61 + (platelets) | 66 | (47;92) | 309 | (230;414) | < 0.0001 |
| CD66 + (neutrophils) | 10 | (8;11) | 16 | (12;22) | 0.0134 |
| CD14 + (macrophages/monocytes) | 10 | (8;14) | 17 | (13;23) | 0.0371 |
| CD105 + (endothelium) | 6 | (5;7) | 15 | (12;20) | < 0.0001 |
| EpCAM + (epithelium) | 8 | (6;11) | 16 | (11;23) | 0.0100 |
Repeated measure analysis with poisson regression models (N = 6).
Figure 3Spaghetti plot and box plot of EV subtypes from subjects exposed to low-PM and high-PM levels. EV subtypes are expressed as count *103/mL PL. Red dots and lines represent OW subjects, green dots and lines represent NW subjects. Black dots and lines represent the mean of all subjects.
Mean concentrations of plasmatic EV subtypes from subjects exposed to low-PM and high-PM levels, stratified for BMI (< or ≥ 25 kg/m2).
| EV characterization (*103/mL PL) | Normal weight: BMI < 25 kg/m2 | Overweight: BMI ≥ 25 kg/m2 | P-value for interaction | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (N = 3) | (N = 3) | ||||||||||
| Low-PM | High-PM | P-value | Low-PM | High-PM | P-value | ||||||
| Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | ||||
| CD61 + (platelets) | 52 | (46;59) | 220 | (154;315) | < 0.0001 | 87 | (53;142) | 428 | (281;650) | 0.0002 | 0.7268 |
| CD66 + (neutrophils) | 11 | (9;13) | 17 | (10;29) | 0.1792 | 8 | (6;11) | 16 | (12;21) | 0.0121 | 0.6912 |
| CD14 + (macrophages/monocytes) | 15 | (10;22) | 18 | (13;26) | 0.3701 | 6 | (5;7) | 16 | (11;24) | 0.0003 | 0.0306 |
| CD105 + (endothelium) | 8 | (7;9) | 19 | (13;27) | < 0.0001 | 5 | (3;7) | 12 | (8;18) | 0.0003 | 0.7287 |
| EpCAM + (epithelium) | 8 | (5;13) | 18 | (9;33) | 0.0967 | 8 | (5;11) | 14 | (12;17) | 0.0001 | 0.6597 |
Repeated measure analysis with poisson regression models.
Figure 4(A) Number of EVs (*108) for each size (nm) from NW subjects exposed to low-PM and high-PM levels. (B) For each size P-value and False Discovery Rate P-value from poisson regression models with repeated meausured are reported.
Figure 5(A) Number of EVs (*108) for each size (nm) produced by cells treated with EVs from OW subjects, exposed to low-PM and high-PM levels. (B) For each size P-value and False Discovery Rate P-value from Poisson regression models with repeated measured are reported.
Mean of cellular EV subtypes isolated after treatments with EVs from subjects exposed to low-PM and high-PM levels, stratified for BMI (< or ≥ 25 kg/m2).
| EV characterization (*103/mL PL) | Cells treated with NW EVs: BMI < 25 kg/m2 | Cells treated with OW EVs: BMI ≥ 25 kg/m2 | P-value for interaction | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (N = 3) | (N = 3) | ||||||||||
| Low-PM | High-PM | P-value | Low-PM | High-PM | P-value | ||||||
| Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | ||||
| Number of CD105 + EV *105 (endothelium) | 197 | (147;264) | 126 | (118;135) | 0.0004 | 94 | (79;112) | 200 | (188;218) | < 0.0001 | < 0.0001 |
| Number of CD62E + EV *105 (activated endothelium) | 245 | (191;313) | 425 | (363;497) | 0.0007 | 99 | (97;100) | 169 | (159;179) | < 0.0001 | 0.9383 |
| Ratio CD62E+/CD105+ | 1.39 | (0.86;2.25) | 3.38 | (2.85;4.02) | < 0.0001 | 1.08 | (0.87;2.25) | 0.84 | (0.82;0.86) | 0.0207 | < 0.0001 |
Repeated measure analysis with poisson regression models. Amounts of cellular EVs are expressed as fold change between EVs isolated from culture media of treated and untreated cells (taken as controls).
Figure 6Average changes of CD62e+/CD105 + ratio with 95% CI after cells treatments with low- and high-PM plasmatic EVs stratified for BMI (< or ≥ 25 kg/m2). Repeated measure analysis with Poisson regression model.